EUVIMEDEUVIMED entdecken
Crossref

Continuous dosing of nikkomycin Z against systemic candidiasis, in vivo and in vitro correlates

Gabriele Sass iD, David J Larwood, Marife Martinez, David A Stevens

Mycoses · 2023

DOI: 10.1111/myc.13569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, 2023. Verfasst von Gabriele Sass und 3 weiteren Autor:innen. Beteiligte Einrichtung: California Institute for Medical Research, San Jose, California, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Candidiasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: David and Mary Larwood Family Charitable Fund, Foundation for Research in Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Candidiasis is the most common cause of fungal sepsis, and new agents are of interest to ameliorate current deficiencies in therapy. Nikkomycin Z (NIKZ) is an inhibitor of chitin synthase, interfering with fungal cell wall development. Objectives/Methods We studied NIKZ therapy of disseminated murine candidiasis, via continuous drug exposure, in drinking water, to compensate for rapid clearance of the drug.

Results

Drinking, and thus drug intake in the NIKZ groups, as well as body weight, was affected by the degree of illness. NIKZ effect on survival, despite reduced drinking initially after infection, was highly efficacious and dose‐related, and comparable to fluconazole, though neither were curative with the regimens employed. The challenge was rapidly lethal to all untreated animals, whereas NIKZ groups achieved >50% survival. Assays of residual fungal infection were consistent with impressions of efficacy based on survival. Although NIKZ MIC for Candida albicans appeared unpromising, mycelial formation assays more closely correlated with in vivo observations.

Conclusions

In vitro ‐ in vivo disparity may be explained by NIKZ tissue concentration in the target tissue and/or by enhanced NIKZ action on mycelial formation, a morphological change in vivo wherein chitin synthesis is more critical, compared to NIKZ activity in inhibiting planktonic growth. A sustained release oral form of NIKZ in drug development for humans could hold promise, possibly also in future exploring previously demonstrated synergy in vitro with other antifungals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandidiasisHumansMiceAnimalsAminoglycosidesCandida albicansMicrobial Sensitivity TestsFluconazole

Stichwörter der Autor:innen

Candida albicansantifungal therapycombination therapyfluconazolenikkomycin Zsystemic candidiasis

Substanzen

nikkomycinAntifungal AgentsAminoglycosidesFluconazole

Autor:innen und Institutionen

  • California Institute for Medical Research, San Jose, California, USA.
  • Valley Fever Solutions, Tucson, Arizona, USA.
  • Div. of Infectious Diseases and Geographic Medicine, Stanford Univ. Medical School, Stanford, California, USA.

ORCID-Profile: Gabriele Sass

Förderung

  • David and Mary Larwood Family Charitable Fund
  • Foundation for Research in Infectious Diseases

Zitieren

APA

Sass, G., Larwood, D. J., Martinez, M., & Stevens, D. A. (2023). Continuous dosing of nikkomycin Z against systemic candidiasis, in vivo and in vitro correlates. Mycoses. https://doi.org/10.1111/myc.13569

Vancouver

Sass G, Larwood DJ, Martinez M, Stevens DA. Continuous dosing of nikkomycin Z against systemic candidiasis, in vivo and in vitro correlates. Mycoses. 2023. doi:10.1111/myc.13569

BibTeX
@article{Sass2023,
  author = {Sass, Gabriele and Larwood, David J and Martinez, Marife and Stevens, David A},
  title = {Continuous dosing of nikkomycin Z against systemic candidiasis, in vivo and in vitro correlates},
  journal = {Mycoses},
  year = {2023},
  doi = {10.1111/myc.13569}
}
Kostenlos starten →